Those who put existing dnigs
to a new use can already obtain a patent on that new use, but use patents are generally considered inferior to a patent on the chemical itself.
73, at n.127 (2010) (That label "includes drag indications, contraindications, instructions for use, warnings and similar information."); and Labeling Requirements for Prescription Dnigs
and/or Insulin, 21 C.F.R.
"This research will aid in the development of the next generation of dnigs
that make repairs and regeneration within the body possible following damage by such factors as cancer, aging, heart disease, diabetes, or paralysis caused by traumatic injury."